{"classes":[{"categories":[{"measurements":[{"comment":"The 95% CI was not available due to insufficient numbers of participants with events.","groupId":"OG000","lowerLimit":"13.93","upperLimit":"NA","value":"16.13"},{"groupId":"OG001","lowerLimit":"9.82","upperLimit":"13.40","value":"10.84"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"207"}],"units":"Participants"}],"description":"TTNT is defined as the duration from date of randomization to start of next anti-MM treatment or death, whichever occurs first. For patients without an event, their follow-up time will be censored at the date of discontinuation from study, or last participating visit on or before database cutoff date, whichever occurs first.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received a fixed oral dose of 100 milligrams (mg) selinexor tablets (5 tablets of 20 mg each) once weekly (QW) on Days 1, 8, 15, 22, and 29 of each 35-day cycle, along with subcutaneous (SC) injection of 1.3 milligrams per square meter (mg/m\\^2) bortezomib QW on Days 1, 8, 15, and 22 of each 35-day cycle, and an oral dose of 20 mg of dexamethasone twice weekly (BIW) on Days 1, 2, 8, 9, 15, 16, 22, 23, 29, and 30 of each 35-day cycle until PD confirmed by the IRC, investigator or participant decision to discontinue study treatment, pregnancy, unacceptable AEs or toxicity that could not be managed by supportive care, withdrawal of consent, death, or sponsor decision to terminate the study.","id":"OG000","title":"SVd Arm: Selinexor + Bortezomib + Dexamethasone"},{"description":"Participants received SC injection of 1.3 mg/m\\^2 bortezomib on Days 1, 4, 8, and 11 of each 21-day cycle for the first 8 cycles, followed by \\>= 9 cycles on Days 1, 8, 15, and 22 of each 35-day cycle, and received oral dose of 20 mg dexamethasone BIW on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21-day cycle for the first 8 cycles and for cycles \\>= 9 on Days 1, 2, 8, 9, 15, 16, 22, 23, 29, and 30 of each 35-day cycle until PD confirmed by the IRC, investigator or participant decision to discontinue study treatment, pregnancy, unacceptable AEs or toxicity that could not be managed by supportive care, withdrawal of consent, death, or sponsor decision to terminate the study.","id":"OG001","title":"Vd Arm: Bortezomib + Dexamethasone"}],"paramType":"MEDIAN","populationDescription":"The ITT population consisted of all participants who were randomized to the study treatment, regardless of whether or not they received the study treatment. Data was not planned to be reported for SVdx arm and Sdx arm.","reportingStatus":"POSTED","timeFrame":"From date of randomization to start of next anti-MM treatment or death, whichever occurred first (up to 33 months)","title":"SVd/Vd Arm: Time-to-next-treatment (TTNT) in Participants Randomized to the SVd and Vd Arm Who Received Treatment After SVd/Vd","type":"SECONDARY","unitOfMeasure":"Months"}